

Corporate Fact Sheet

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody technologies.

Company Highlights

- Emerging leader in developing immuno-oncology therapeutics
- Pipeline comprising ten differentiated clinical-stage product candidates
- Leading multispecific antibody technology platforms, with seven DART® molecules in clinic
- Fully-integrated mAb-based development capabilities, including GMP manufacturing
- Collaborations with Incyte, Janssen, Servier, Pfizer and Boehringer Ingelheim
- Experienced management team and highly collaborative corporate culture

Pipeline

Program (Target)	Indication	Pre-IND	Phase 1	Phase 2	Phase 3	Collaborator
ONCOLOGY						
margetuximab (HER2)	Breast (HER2+) "SOPHIA"					Green Cross (Korea only)
	Gastric (+anti-PD-1)					
enoblituzumab (B7-H3)	Solid Tum. (+anti-PD-1)					—
	Solid Tum. (monotherapy)					
flotetuzumab (CD123 x CD3)	AML/MDS					Servier (EU, Other)
MGD007 (gpA33 x CD3)	Colorectal					—
MGD009 (B7-H3 x CD3)	Solid Tumors					—
MGA012 (PD-1)	Solid Tumors					Incyte ^(b)
MGD013 (PD-1 x LAG-3)	Solid Tumors/Heme Mal.					—
MGC018 (B7-H3) ^(a)	Solid Tumors					—
MGD019 (PD-1 x CTLA-4)	Solid Tumors					—
AUTOIMMUNE & INFECTIOUS DISEASES						
teplizumab (CD3)	Type 1 Diabetes Prev.					NIDDK/NIH
MGD010 (CD32B x CD79B)	Autoimmune Disorders					—
MGD014 (HIV x CD3)	HIV					NIAID/NIH

(a) ADC based on duocarmycin payload with cleavable peptide linker licensed from Synthron Biopharmaceuticals.

(b) MacroGenics retains rights to develop its pipeline assets in comb. w/MGA012 and manuf. portion of global clinical & commercial supply needs of MGA012.

DART mAb ADC

MacroGenics' Antibody Formats

DART and TRIDENT™ therapeutics enable the targeting of multiple antigens or cells with a single antibody-like molecule. Applications include the recruitment of a patient's T cells to destroy targeted cancer cells and the engagement of two checkpoint inhibitors for improved activation of the immune system. The flexibility of this platform allows for the design of molecules with increased half-life and valency compared to other multi-specific approaches.

Fc-Optimized antibodies mediate the killing of cancer cells through antibody-dependent cellular cytotoxicity, or ADCC, in which antibodies and immune cells cooperate to destroy targets such as tumor cells.

Quick Facts

Employees:

324 (as of 10/18/17)

Cash & Investments:

\$244M at 6/30/17

(Excludes \$150M upfront from Incyte as part of MGA012 collaboration - expected to close 4Q17)

Shares Outstanding:

36.8M at 7/31/17

Ticker:

MGNX (NASDAQ)

Locations:

Rockville, MD

South San Francisco, CA

Platforms:

DART (bispecific)

TRIDENT (trispecific)

Fc Optimization

Cancer Stem-like Cells

Key Collaborations

MacroGenics has developed significant alliances with leading pharmaceutical and biotechnology companies. Ongoing collaboration partners that have provided significant non-dilutive funding include:



October 2017



May 2016



September 2012



October 2010



October 2010

Management

Scott Koenig, M.D., Ph.D.
President and CEO

James Karrels
SVP, CFO

Ezio Bonvini, M.D.
SVP, Research and
Chief Scientific Officer

Eric Risser
SVP, Chief Business Officer

Tom Spitznagel, Ph.D.
SVP, BioPharmaceutical
Dev't and Manufacturing

Jon Wigginton, M.D.
SVP, Clinical Development &
Chief Medical Officer

Syd Johnson, Ph.D.
VP, Antibody Engineering

Paul Moore, Ph.D.
VP, Immunology &
Cell Biology

Jeffrey Peters
VP, Legal Affairs and
Acting General Counsel

James Vasselli, M.D.
VP, Clinical Research

Board of Directors

Paulo Costa (Chairman)
Former President & CEO,
Novartis Pharmaceuticals, US

Karen Ferrante, M.D.
Former CMO, Head of Rsch.,
Tokai Pharmaceuticals

Matthew Fust
Former CFO,
Onyx Pharmaceuticals

Kenneth Galbraith
General Partner,
Five Corners Capital

Edward Hurwitz
Managing Director,
MPM Capital

Scott Jackson
Former CEO,
Celator Pharmaceuticals

Scott Koenig, M.D., Ph.D.
President and CEO,
MacroGenics

David Stump, M.D.
Former EVP of R&D,
Human Genome Sciences


Monoclonal Antibodies in Clinical Development

Margetuximab (HER2)

Fc-optimized mAb

Phase 3

Margetuximab is an Fc-optimized mAb that targets HER2-expressing tumors, including breast and gastroesophageal cancers. MacroGenics has engineered the Fc region of margetuximab to enhance its Fc-mediated effects, including improved ADCC. MacroGenics is conducting a Phase 3 registration trial (SOPHIA) in mBC patients to demonstrate clinical superiority to trastuzumab. The Company is also enrolling a Phase 1b/2 study for the treatment of advanced gastric cancer in combination with an anti-PD-1 agent.



Enoblituzumab (B7-H3)

Fc-optimized mAb

Phase 1b/2

MacroGenics is developing a portfolio of first-in-class therapeutics that target B7-H3, a member of the B7 family of molecules involved in immune regulation and believed to inhibit T-cell activation. Enoblituzumab is an Fc-optimized monoclonal antibody that targets B7-H3 to take advantage of this antigen's broad expression across solid tumors. The Company is completing enrollment of monotherapy studies in patients with prostate, bladder and pediatric tumors. MacroGenics also continues to enroll patients in a combination study with anti-PD-1.

MGA012 (PD-1)

mAb

Phase 1

MGA012 is a humanized, proprietary anti-PD-1 monoclonal antibody. In October 2017, MacroGenics entered into an exclusive global collaboration and license agreement with Incyte Corporation for MGA012, in which Incyte obtained exclusive worldwide rights for the development and commercialization of the molecule in all indications, while MacroGenics retains the right to develop its pipeline assets in combination with MGA012.

DART Molecules in Clinical Development

Program (target)	Dev't Stage	Indications	Partner	MacroGenics' Rights
Redirected T-Cell Killing:				
Flotetuzumab (CD123 x CD3)	Phase 1	AML, MDS	Servier	North America, Japan, Korea, India
MGD007 (gpA33 x CD3)	Phase 1	Colorectal cancer	Servier (option)	North America, Japan, Korea, India
MGD009 (B7-H3 x CD3)	Phase 1	Solid tumors	—	Worldwide
MGD014 (HIV x CD3)	IND Sub.	HIV	NIAID/NIH	Worldwide
PF-06671008 (P-cadherin x CD3)	Phase 1	Solid tumors	Pfizer	Royalties and milestones
Checkpoint Co-blockade:				
MGD013 (PD-1 x LAG-3)	Phase 1	Solid tumors, heme	—	Worldwide
Signal Modulation:				
MGD010 (CD32B x CD79B)	Ph. 1 SAD completed	Autoimm. disord.	—	Worldwide